Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population
Maureen Kubacki, PharmD, MBA , Chureen Carter, PharmD, MS , Alan D. L. Herrera, PharmD, Jim Wang, PhD, Janice M.S. Lopez, PharmD, MPH, Catherine T. Piech, MBA
Chronic kidney disease (CKD) affects approximately 26 million people in the United States.1 Diabetes and hypertension cause up to two thirds of all new CKD cases.1,2 According to Medicare policy, health plans are financially responsible for the care of CKD patients for up to 33 months after they have reached the final stage of end-stage renal disease (ESRD).3 Data from the Institute for Health and Productivity Management 2001 database show that treatment costs nearly double from one stage of CKD to the next.4 The stages of CKD are defined based on
Alignment of Incentives along the Healthcare Payer Continuum for Patients with Kidney Disease
Impact of Prescription Benefit Coverage Limits on Sevelamer Hydrochloride Adherence for Patients with ESRD
Hyperphosphatemia is prevalent among patients with end-stage renal disease (ESRD) and continues to be an important and challenging area for drug therapy.
Balancing Horizontal and Vertical Equity within Managed Health Plans Drug Benefit
Nancy M. McGee, JD, MPH, Gene Reeder, RPh, PhD, Timothy S. Regan, BPharm, RPh, CPh, J.D. Kleinke, Steve Arnold, MD, MS, MBA, CPE
Across socioeconomic strata, American households are adopting an increasingly electronic way of life. Bills are routinely paid online, bank balances are tracked, goods are purchased, and music is downloaded at record consumer adoption rates.1 Income levels, bank balances, and consumer preferences are routinely shared and stored in the electronic ether. There is a unity of confidence and comfort on behalf of the consumer and the vendor that these personal pieces of information are safe and secure.
Electronic PHRs and e-Prescribing: Not Quite There Yet
Pharmaceutical manufacturers face an increasing drug utilization dilemma—not related to formulary acceptance—in the US marketplace regarding patent expiration, new-entry pharmaceuticals, and biotechnology products. Influencers of health plan reimbursement program decision makers (eg, benefit managers, consultants, consumer advocates) and reimbursement transaction platforms need more attention from pharmaceutical marketers and senior executives in relation to their current and emerging product pipeline.
The Many Challenges of Pay-for-Performance Programs
Impact of Etanercept Treatment on Absenteeism and Productivity: The Work Loss and Productivity Survey
Denise Globe, PhD, Peter Mazonson, MD, MBA, Chris Santas, MBA, Regina Murphy, MBA, Annie Cheng, Xingyue Huang, PhD, Arthur Kavanaugh, MD
Rheumatoid arthritis (RA) is a chronic, disabling autoimmune disorder that affects approximately 1% of American adults.1 There has been substantial progress in our understanding of RA disease progression and in the development of therapies for its treatment in recent years.
What Is the Value of Specialty Pharmaceuticals?
Page 13 of 13
Results 121 - 125 of 125
Results 121 - 125 of 125